Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.

Cytochrome P450 2C8 (CYP2C8) is one of the enzymes primarily responsible for the metabolism of many drugs, including paclitaxel and amodiaquine. CYP2C8 genetic variants contribute to interindividual variations in the therapeutic efficacy and toxicity of paclitaxel. Although it is difficult to investigate the enzymatic function of most CYP2C8 variants in vivo, this can be investigated in vitro using recombinant CYP2C8 protein variants. The present study used paclitaxel to evaluate 6α-hydroxylase activity and amodiaquine for the N-deethylase activity of wild-type and 11 CYP2C8 variants resulting in amino acid substitutions in vitro. The wild-type and variant CYP2C8 proteins were heterologously expressed in COS-7 cells. Paclitaxel 6α-hydroxylation and amodiaquine N-deethylation activities were determined by measuring the concentrations of 6α-hydroxypaclitaxel and N-desethylamodiaquine, respectively, and the kinetic parameters were calculated. Compared to the wild-type enzyme (CYP2C8.1), CYP2C8.11 and CYP2C8.14 showed little or no activity with either substrate. In addition, the intrinsic clearance values of CYP2C8.8 and CYP2C8.13 for paclitaxel were 68% and 67% that of CYP2C8.1, respectively. In contrast, the CLint values of CYP2C8.2 and CYP2C8.12 were 1.4 and 1.9 times higher than that of CYP2C8.1. These comprehensive findings could inform for further genotype-phenotype studies on interindividual differences in CYP2C8-mediated drug metabolism.

[1]  B. Psaty,et al.  Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. , 2011, Biochemical pharmacology.

[2]  Ituro Inoue,et al.  A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin , 2004, Journal of Human Genetics.

[3]  L. Teh,et al.  Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. , 2008, Drug metabolism and pharmacokinetics.

[4]  F. Zhong,et al.  Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8 , 2011, Amino Acids.

[5]  M. Sawyer,et al.  Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. , 2007, Pharmacogenomics.

[6]  Yoshiro Saito,et al.  Influence of CYP2C8*13 and CYP2C8*14 Alleles on Amiodarone N‐Deethylation , 2011, Basic & clinical pharmacology & toxicology.

[7]  W. Vach,et al.  Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer , 2011, The Pharmacogenomics Journal.

[8]  R. Frye,et al.  Determination of N-desethylamodiaquine by hydrophilic interaction liquid chromatography with tandem mass spectrometry: application to in vitro drug metabolism studies. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[9]  L. Carey,et al.  Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy , 2014, Breast Cancer Research and Treatment.

[10]  R. Milne,et al.  Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity , 2011, The Pharmacogenomics Journal.

[11]  S. Zeng,et al.  Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro , 2013, Biopharmaceutics & drug disposition.

[12]  M. Relling,et al.  Variability in human cytochrome P450 paclitaxel metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.

[13]  C David Stout,et al.  Structure of Human Microsomal Cytochrome P450 2C8 , 2004, Journal of Biological Chemistry.

[14]  J. Goldstein,et al.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. , 2001, Pharmacogenetics.

[15]  Yoshiro Saito,et al.  Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. , 2002, Drug metabolism and pharmacokinetics.

[16]  Teruhiko Yoshida,et al.  CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population , 2007, Pharmacogenetics and genomics.

[17]  Yoshiro Saito,et al.  Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. , 2001, Biological & pharmaceutical bulletin.

[18]  C. Aquilante,et al.  Influence of CYP2C8*2 on the Pharmacokinetics of Pioglitazone in Healthy African‐American Volunteers , 2013, Pharmacotherapy.

[19]  Duan Liu,et al.  Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  D. Lewis,et al.  Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  N. Matsumoto,et al.  Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. , 2005, Journal of pharmacological sciences.

[22]  Shu-Feng Zhou,et al.  Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. , 2009, Current drug metabolism.

[23]  Yoshiro Saito,et al.  Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel. , 2010, Basic & clinical pharmacology & toxicology.

[24]  Anders Karlén,et al.  Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[25]  C. Caldas,et al.  Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel , 2014, Clinical Cancer Research.

[26]  H. Gréen,et al.  Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer. , 2011, Journal of pharmaceutical sciences.

[27]  P. Kwok,et al.  Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis , 2010, Pharmacogenetics and genomics.

[28]  P. Söderkvist,et al.  Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. , 2009, Basic & clinical pharmacology & toxicology.

[29]  Tetsuya Terasaki,et al.  Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities , 2012, Drug Metabolism and Disposition.

[30]  L. Carey,et al.  CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel , 2012, Breast Cancer Research and Treatment.

[31]  Eun-Young Kim,et al.  Discovery of a Novel Allelic Variant of CYP2C8, CYP2C8*11, in Asian Populations and Its Clinical Effect on the Rosiglitazone Disposition In Vivo , 2011, Drug Metabolism and Disposition.

[32]  R. Altman,et al.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8 , 2012, Pharmacogenetics and genomics.

[33]  P. Rosenthal,et al.  Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa , 2007, Clinical pharmacology and therapeutics.

[34]  Yoshiro Saito,et al.  Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. , 2002, Pharmacology & toxicology.

[35]  Teruhiko Yoshida,et al.  FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP2C8 VARIANTS, G171S, R186X, R186G, K247R, AND K383N, FOUND IN A JAPANESE POPULATION , 2005, Drug Metabolism and Disposition.